peptide boronic acidCancer Research Peptides
Bortezomib (Velcade)
A modified dipeptidyl boronic acid proteasome inhibitor. FDA-approved for multiple myeloma and mantle cell lymphoma. First-in-class proteasome inhibitor. Reversibly inhibits the 26S proteasome.
proteasome-inhibitormultiple-myelomacancer-treatmentFDA-approved
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A modified dipeptidyl boronic acid proteasome inhibitor. FDA-approved for multiple myeloma and mantle cell lymphoma. First-in-class proteasome inhibitor. Reversibly inhibits the 26S proteasome.